Overview

GelMEDIX is a regenerative medicine company committed to combatting vision loss with our groundbreaking biomaterials platform. 

​

Our lead program is focused on preserving vision for patients suffering from Geographic Atrophy (GA), the leading cause of blindness in adults over 60. With no approved therapies maintain vision, patients continue to lose their independence. Regenerative medicine, specifically, retinal pigment epithelial (RPE) cell therapy has the potential to transform care by regenerating lost retina and preserving vital structures required for vision. 

​

Our iPSC-derived RPE cell therapy utilizes an advanced hydro scaffold, demonstrating remarkable visual preservation for up to 92 days in preclinical studies, all while eliminating the risks that have plagued previous therapies. Join us on this exciting journey toward restoring sight!